BioSpace News Archive

AVROBIO, Inc., a leading clinical-stage gene therapy company, announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma (“DIPG”).

Neuropathix, Inc. (OTCQB: NPTX), formerly Kannalife, Inc. (the “Company” or “Neuropathix”), a socially responsible pain management life sciences company, announced today it has entered into a binding letter of intent to acquire a suite of sulfamide-containing neuroprotective compounds containing substructures known to produce anticonvulsant activity, as a means to provide both neuroprotection and anticonvulsant activity in the same drug candidate.

Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced new clinical results from its Phase 1 study evaluating rivoceranib (apatinib)

Allos Pharma Inc, a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, has announced the exclusive license rights on arbaclofen in Fragile X Syndrome (FXS).

Today, Bright Health Inc. announced that former Periscope CEO Elizabeth Ross will be joining the Company as its new Chief Marketing Officer on Monday, November 30.

Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience.

HeartFlow, Inc., a leader in revolutionizing precision heartcare, has named Julie Cullivan, Chief Information Officer of Forescout Technologies, Inc., the leader in Enterprise of Things security, to its Board of Directors, effective November 19, 2020.

AbCellera, a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease, announced the appointment of Peter Thiel to its Board of Directors.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced it has been ranked 13th in revenue growth among all medical device companies in